STOCK TITAN

hik - $hik STOCK NEWS

Welcome to our dedicated page for hik news (Ticker: $hik), a resource for investors and traders seeking the latest updates and insights on hik stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect hik's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of hik's position in the market.

Rhea-AI Summary
Hikma Pharmaceuticals collaborates with the Office of National Drug Control Policy to combat the opioid overdose epidemic in the US, focusing on expanding access to naloxone. The company welcomed Dr. Rahul Gupta to its Columbus facility for discussions and a tour regarding the production of overdose reversal medicine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Hikma Pharmaceuticals PLC announces the launch of COMBOGESIC IV, an opioid-free pain relief medicine in the US. The medicine is a combination of acetaminophen and ibuprofen approved by the US FDA for adult pain management. It provides superior analgesia efficacy and shorter onset to analgesia compared to individual drugs. The Phase 3 clinical trial showed more than double pain relief compared to individual drugs, making it a promising alternative for hospitals and healthcare providers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Activ Surgical completes its first international surgery at Abdali Hospital in Jordan using its ActivSight technology, which provides enhanced visualization and real-time surgical insights. Dr. Mohamad Rassoul Abu-Nuwar, trained at the Esophageal Institute - West Penn Hospital, performed a surgical bariatric revision procedure using ActivPerfusion Mode. Hikma Ventures, a lead investor, supports the global expansion of ActivSight.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.89%
Tags
none
Rhea-AI Summary
Guardant Health, Inc. (Nasdaq: GH) and Hikma Pharmaceuticals PLC announced a partnership to promote Guardant Health’s cancer screening and monitoring tests in the Middle East and North Africa. The agreement aims to improve access to next-generation sequencing tests in the region, where cancer cases are estimated to double by 2040.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.38%
Tags
partnership
-
Rhea-AI Summary
Guardant Health, a leading precision oncology company (Nasdaq: GH), partners with Hikma Pharmaceuticals PLC to promote its cancer screening and tumor mutation profiling tests in the Middle East and North Africa. The agreement provides Hikma with exclusive rights to commercialize Guardant Health's products in the majority of countries in the MENA region. This partnership aims to improve access to next-generation sequencing tests in a region where cancer cases are estimated to double by 2040.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.38%
Tags
partnership
-
Rhea-AI Summary
Hikma Pharmaceuticals announces donation of over 375,000 doses of KLOXXADO® to combat opioid overdose epidemic
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.17%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-100%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.08%
Tags
hik

OTC:HIK

HIK Rankings

HIK Stock Data